Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human VEGF165 Protein (premium grade), 50µg  

Recombinant Human VEGF165 Protein (premium grade), 50µg

Recombinant Human VEGF165 Protein, Ala 27 - Arg 191, was produced in human 293 cells (HEK293),  premium grade

Synonyms: Vascular endothelial growth factor A-165, RP1-261G23.1, MGC70609, MVCD1, VEGFA, VPF

More details

VE5-H4210-050

Availability: within 7 days

442,00 €

Background:
VEGF165 is the most abundant splice variant of VEGF-A [1,2]. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

Source
Recombinant Human VEGF165, premium grade(VE5-H4210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).
Predicted N-terminus: Ala 27
It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 19.2 kDa. The protein migrates as 24 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.01 EU per μg by the LAL method.

Host Cell Protein
<0.5 ng/μg of protein tested by ELISA.

Host Cell DNA
<0.02 ng/μg of protein tested by qPCR.

Sterility
The sterility testing was performed by membrane filtration method.

Mycoplasma
Negative.

Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Directed Differentiation of Human Induced Pluripotent Stem Cells to Heart Valve Cells"
Cai, Zhu, Xu et al
Circulation (2024)
(2) "A colorimetric immunoassay for the detection of human vascular endothelial growth factor 165 (VEGF165) based on anti-VEGF-iron oxide nanoparticle conjugation"
Ceylan, Kırbay, Yazgan et al
Mikrochim Acta (2024) 191 (3), 133
(3) "A Review of Genes Involved in Wound Healing"
Farhangniya, Samadikuchaksaraei
Med J Islam Repub Iran (2023) 37, 140
Showing 1-3 of 1911 papers

 

 

The following products could also be interesting for you: